Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
MASS Quote, Financials, Valuation and Earnings
Last price:
$5.45
Seasonality move
:
10.95%
Day range:
$5.20 - $5.46
52-week range:
$1.92 - $9.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
1.43x
Volume:
491.7K
Avg. volume:
506.7K
1-year change:
145.45%
Market cap:
$195.4M
Revenue:
$59.6M
EPS (TTM):
-$1.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MASS
908 Devices, Inc.
|
$15.8M | -$0.06 | -15.82% | -90.19% | $10.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
NSPR
InspireMD, Inc.
|
$2.6M | -$0.20 | 34.51% | -6.61% | $4.50 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MASS
908 Devices, Inc.
|
$5.40 | $10.00 | $195.4M | -- | $0.00 | 0% | 3.33x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.77 | $14.20 | $178.3M | 33.54x | $0.00 | 0% | 1.32x |
|
NSPR
InspireMD, Inc.
|
$1.81 | $4.50 | $76.7M | -- | $0.00 | 0% | 12.99x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34M | -- | $0.00 | 0% | 18.97x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.71 | $1.50 | $99.4M | 69.62x | $0.00 | 0% | 0.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MASS
908 Devices, Inc.
|
3.1% | -4.230 | 1.38% | 2.97x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
NSPR
InspireMD, Inc.
|
5% | 0.424 | 3.34% | 6.04x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MASS
908 Devices, Inc.
|
$6.9M | -$5.5M | -39.85% | -41.37% | -39.39% | -$4.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
NSPR
InspireMD, Inc.
|
$864K | -$13.1M | -113.89% | -121.49% | -517.28% | -$9M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
908 Devices, Inc. vs. Competitors
-
Which has Higher Returns MASS or CATX?
Perspective Therapeutics, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -12425.36%. 908 Devices, Inc.'s return on equity of -41.37% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital MASS908 Devices, Inc.49.26% -$0.41 $140.7M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About MASS or CATX?
908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 85.19%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than 908 Devices, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than 908 Devices, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MASS908 Devices, Inc.3 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is MASS or CATX More Risky?
908 Devices, Inc. has a beta of 0.482, which suggesting that the stock is 51.757% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock MASS or CATX?
908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MASS or CATX?
908 Devices, Inc. quarterly revenues are $14M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. 908 Devices, Inc.'s net income of -$14.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 3.33x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MASS908 Devices, Inc.3.33x -- $14M -$14.9M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns MASS or INFU?
InfuSystem Holdings, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of 6.19%. 908 Devices, Inc.'s return on equity of -41.37% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital MASS908 Devices, Inc.49.26% -$0.41 $140.7M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About MASS or INFU?
908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 85.19%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61.92%. Given that 908 Devices, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe 908 Devices, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MASS908 Devices, Inc.3 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is MASS or INFU More Risky?
908 Devices, Inc. has a beta of 0.482, which suggesting that the stock is 51.757% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock MASS or INFU?
908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MASS or INFU?
908 Devices, Inc. quarterly revenues are $14M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. 908 Devices, Inc.'s net income of -$14.9M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 3.33x versus 1.32x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MASS908 Devices, Inc.3.33x -- $14M -$14.9M INFUInfuSystem Holdings, Inc.1.32x 33.54x $36.5M $2.3M
-
Which has Higher Returns MASS or NSPR?
InspireMD, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -503.69%. 908 Devices, Inc.'s return on equity of -41.37% beat InspireMD, Inc.'s return on equity of -121.49%.
Company Gross Margin Earnings Per Share Invested Capital MASS908 Devices, Inc.49.26% -$0.41 $140.7M NSPRInspireMD, Inc.34.25% -$0.17 $67.5M -
What do Analysts Say About MASS or NSPR?
908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 85.19%. On the other hand InspireMD, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 148.62%. Given that InspireMD, Inc. has higher upside potential than 908 Devices, Inc., analysts believe InspireMD, Inc. is more attractive than 908 Devices, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MASS908 Devices, Inc.3 0 0 NSPRInspireMD, Inc.1 0 0 -
Is MASS or NSPR More Risky?
908 Devices, Inc. has a beta of 0.482, which suggesting that the stock is 51.757% less volatile than S&P 500. In comparison InspireMD, Inc. has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.574%.
-
Which is a Better Dividend Stock MASS or NSPR?
908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InspireMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. InspireMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MASS or NSPR?
908 Devices, Inc. quarterly revenues are $14M, which are larger than InspireMD, Inc. quarterly revenues of $2.5M. 908 Devices, Inc.'s net income of -$14.9M is lower than InspireMD, Inc.'s net income of -$12.7M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while InspireMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 3.33x versus 12.99x for InspireMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MASS908 Devices, Inc.3.33x -- $14M -$14.9M NSPRInspireMD, Inc.12.99x -- $2.5M -$12.7M
-
Which has Higher Returns MASS or VNRX?
VolitionRX Ltd. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -862.39%. 908 Devices, Inc.'s return on equity of -41.37% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MASS908 Devices, Inc.49.26% -$0.41 $140.7M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About MASS or VNRX?
908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 85.19%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 694.8%. Given that VolitionRX Ltd. has higher upside potential than 908 Devices, Inc., analysts believe VolitionRX Ltd. is more attractive than 908 Devices, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MASS908 Devices, Inc.3 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is MASS or VNRX More Risky?
908 Devices, Inc. has a beta of 0.482, which suggesting that the stock is 51.757% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock MASS or VNRX?
908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MASS or VNRX?
908 Devices, Inc. quarterly revenues are $14M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. 908 Devices, Inc.'s net income of -$14.9M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 3.33x versus 18.97x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MASS908 Devices, Inc.3.33x -- $14M -$14.9M VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M
-
Which has Higher Returns MASS or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of 3.93%. 908 Devices, Inc.'s return on equity of -41.37% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital MASS908 Devices, Inc.49.26% -$0.41 $140.7M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About MASS or XTNT?
908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 85.19%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.24%. Given that Xtant Medical Holdings, Inc. has higher upside potential than 908 Devices, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than 908 Devices, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MASS908 Devices, Inc.3 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is MASS or XTNT More Risky?
908 Devices, Inc. has a beta of 0.482, which suggesting that the stock is 51.757% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock MASS or XTNT?
908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MASS or XTNT?
908 Devices, Inc. quarterly revenues are $14M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. 908 Devices, Inc.'s net income of -$14.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 69.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 3.33x versus 0.78x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MASS908 Devices, Inc.3.33x -- $14M -$14.9M XTNTXtant Medical Holdings, Inc.0.78x 69.62x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
